VideaHealth (Videa) Review (2026): The DSO Favorite Hiding Inside Dentrix

Facts & pricing verified July 3, 2026

VideaHealth (rebranding to just “Videa”) is the dental AI you may already be using without knowing it: Henry Schein One white-labels it as Dentrix Detect AI, and it’s the imaging AI behind Aspen Dental, Heartland Dental, dentalcorp, MB2, Sage Dental, and Tend. The company claims 90,000+ clinicians as of mid-2026 — plausibly the largest deployed footprint in the category, achieved mostly through enterprise channels rather than one-doctor sales.

What it actually does

The FDA story is genuinely strong, and unusually verifiable — the K-numbers are public: K213795 (Caries Assist, 2022 — its pivotal trial showed dentists missing 43% fewer caries), K223296 (Perio Assist bone-level measurement), K232384 (Dental Assist, Jan 2024 — 30+ conditions, “virtually all common dental disease,” and the first and only pediatric clearance, ages 3+), and K251002 (March 2025 — panoramic images, ages 3–21, delivered via cloud API).

Around imaging, Videa has been expanding fast: Voice Notes (dental-specific ambient AI scribe, Oct 2025), Voice Perio (hands-free perio charting), practice analytics, and revenue-cycle tools (Clean Claims, AutoVerify).

Pricing

Nothing published; enterprise sales only. Third-party reports are all over the map — $79–$199/month per chair per one revenue-ops aggregator, roughly $600/month per user per forum discussion cited in a competitor’s blog — and none are vendor-confirmed. If you’re a DSO associate, it’s likely bundled invisibly; Tend, for instance, states it’s built into exams at no charge to patients.

Strengths

• Pediatric practices have exactly one FDA-cleared option, and this is it. Ages 3+, primary and mixed dentition.
• The 43%-fewer-missed-caries pivotal trial remains one of the strongest published clinical results in the category.
• Native Dentrix integration — no image export, no second app; findings appear inside the workflow you already use.
• Fleet-proven: Aspen rolled it out chain-wide in six weeks.

Weaknesses

• The independent review vacuum is the real caveat. We could not find substantive Capterra, G2, Reddit, or Dentaltown reviews from actual end users — remarkable for a product claiming 90,000+ clinicians. Public praise is nearly all vendor-curated. Contract terms, support quality, and field accuracy are effectively unverifiable from outside.
• Opaque, sales-led pricing with the least third-party price signal of the big three.
• False positives are enough of a theme that Videa shipped “Caries 3.0” specifically to reduce them, citing its own survey where 67% of practitioners worry about AI reliability.
• Solo practices are not the center of gravity; the product and pricing are built for fleets.

Verdict

Inside a Dentrix/DSO environment — or any pediatric practice — Videa is often the path of least resistance and sometimes the only cleared option. For an independent practice comparison-shopping on published facts, Pearl and Overjet give you far more third-party signal to evaluate. See the Overjet vs VideaHealth head-to-head.

Sources: FDA accessdata PDFs for K213795, K223296, K232384, K251002; BusinessWire clearance, Series B, and Voice Notes releases; Henry Schein One partnership; Becker’s on the Aspen rollout; Videa.